SCHEMBL8738489

SCHEMBL8738489

Cc1nc(Nc2cccnc2)sc1-c1csc(Nc2cc(C(N)=O)ccc2OC(C)C)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.60
MAPT P10636 9/20 0.55
KDM4E B2RXH2 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
HPGD P15428 4/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
TRPV4 Q9HBA0 1/20 0.55
MEN1 O00255 10/20 0.47
KMT2A Q03164 10/20 0.47
GAA P10253 3/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 6/20 0.47
CFTR P13569 3/20 0.47
HTT P42858 3/20 0.47
LMNA P02545 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
ALB P02768 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8738335 0.91 MAPT (0.55) PIK3CGMAPTKDM4ESMN1; SMN2HPGD
SCHEMBL8738338 0.90 TRPV4 (0.52) MAPTKDM4ESMN1; SMN2HPGDTRPV4
SCHEMBL8737954 0.88 MEN1 (0.48) PIK3CGMAPTKDM4ESMN1; SMN2HPGD
SCHEMBL8737774 0.86 MMP9 (0.59) PIK3CGMAPTKDM4ESMN1; SMN2HPGD
SCHEMBL8738405 0.85 MAPT (0.58) PIK3CGMAPTKDM4ESMN1; SMN2HPGD
SCHEMBL8521768 0.85 MEN1 (0.57) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL6114193 0.85 MEN1 (0.58) MAPTKDM4ESMN1; SMN2HPGDMEN1
SCHEMBL8738028 0.85 MEN1 (0.56) MAPTKDM4ESMN1; SMN2HPGDTRPV4
Bromide SCHEMBL6114360 0.85 MMP9 (0.58) PIK3CGMAPTKDM4ESMN1; SMN2HPGD
SCHEMBL8738463 0.85 MEN1 (0.43) PIK3CGMAPTKDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 PIK3CG 4850/4885MAPT 3531/4885KDM4E 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.